STATResearch Highlights

Astellas Reenters Clinic With Next-Generation Gene Therapy for XLMTM

27 Apr 20264 min read0 viewsVerified Feed

GIST

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. New hair loss data for a sort of amped-up minoxidil is looking very plush.

Also Astellas is reentering the clinic with a next-generation gene therapy for XLMTM and Intellia’s CRISPR therapy for hereditary angioedema impresses. The need-to-know this morning Eli Lilly said it is buying Ajax Therapeutics , a privately held developer of blood cancer drugs, for as much as $2.3 billion.

Ajax’s lead medicine is a next-generation JAK2 inhibitor currently being evaluated in a Phase 1 study in patients with myelofibrosis. Ligand Pharmaceuticals said it is buying Xoma , an aggregator of drug royalties, for $739 million.

  Compass Therapeutics said its drug for advanced biliary cancer delayed tumor progression but failed to prolong survival compared to chemotherapy in a clinical trial.  BridgeBio shares were higher this morning on reports from the weekend that Pfizer had settled two of three patent cases regarding Vyndamax, its medicine for the heart condition known as ATTR-CM.

Clinical Editorial

Context and focus

A short industry roundup noted several corporate deals and clinical results; the feed highlighted that Astellas is returning to clinical testing with a next-generation gene therapy for X-linked myotubular myopathy (XLMTM) after prior program fatalities.

The brief also referenced other biotech news including acquisitions and trial readouts.

Design and study details reported

The source did not provide protocol-level information for the Astellas XLMTM program (no description of trial phase, dose regimen, patient selection, or endpoints).

It likewise did not detail the molecular design of the next-generation gene therapy or how it differs from the earlier program associated with adverse events.

Population and exposure described

The only population context explicitly mentioned was XLMTM as the target disease for Astellas’s program.

No patient numbers, demographics, inclusion/exclusion criteria, or prior treatment histories were reported in the source.

Key accompanying biotech highlights

Intellia Therapeutics reported that its single-administration CRISPR therapy, lonvo‑z, reduced attack rates by 87% in a Phase 3 trial for hereditary angioedema, with more than 60% of treated patients becoming attack-free; the company reported no serious safety signals in that announcement.
Corporate transactions summarized included Eli Lilly’s acquisition of Ajax Therapeutics (up to $2.3 billion) and Ligand Pharmaceuticals’ acquisition of Xoma for $739 million.
Other clinical and legal updates were noted: Compass Therapeutics reported a drug that delayed tumor progression but did not extend survival in advanced biliary cancer; BridgeBio’s shares rose on reports that Pfizer settled two of three patent cases concerning Vyndamax, potentially affecting competitive dynamics with BridgeBio’s ATTR‑CM product Attruby.

Safety and prior adverse events

The source states Astellas reentered the clinic “after deaths” linked to its earlier XLMTM gene‑therapy program, but it did not provide details about the number of deaths, timing, causality assessments, or regulatory actions taken.